Ensign Peak Advisors’s NewAmsterdam Pharma NAMS Stock Holding History

Ensign Peak Advisors’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.2M	Sell	212,423 -36,767	-15%	-$1.21M	0.01%	493
2026 Q1	$7.98M	Sell	249,190 -300,321	-55%	-$9.78M	0.01%	453
2025 Q4	$19.3M	Buy	+549,511	New	+$20M	0.03%	297
2024 Q4	–	Sell	-245,571	Closed	-$4.08M	–	1721
2024 Q3	$4.08M	Sell	245,571 -535	-0.2%	-$9.26K	0.01%	697
2024 Q2	$4.73M	Hold	246,106	–	–	0.01%	636
2024 Q1	$5.82M	Buy	246,106 +54,150	+28%	+$1.1M	0.01%	587
2023 Q4	$2.14M	Sell	191,956 -245,777	-56%	-$2.25M	﹤0.01%	891
2023 Q3	$4.05M	Sell	437,733 -4,223	-1%	-$45.7K	0.01%	629
2023 Q2	$5.25M	Buy	441,956 +86,956	+24%	+$1.15M	0.01%	570
2023 Q1	$4.71M	Hold	355,000	–	–	0.01%	584
2022 Q4	$3.87M	Buy	+355,000	New	+$3.53M	0.01%	624

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Ensign Peak Advisors's NAMS Position: Q2 2026 in Review

Ensign Peak Advisors reduced its NewAmsterdam Pharma (NAMS) stake by 15% in Q2 2026, selling an estimated $1.21M and leaving 212,423 shares worth $7.2M. The position accounts for 0.01% of the portfolio, ranked #493.

Ensign Peak Advisors first reported a position in NAMS in Q4 2022 and has held it in 11 quarters since. The position peaked at $19.3M in Q4 2025. 195 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

Ensign Peak Advisors held 212,423 shares of NewAmsterdam Pharma worth $7.2M as of Q2 2026.
Ensign Peak Advisors sold 36,767 NewAmsterdam Pharma shares in Q2 2026, an estimated $1.21M.
NewAmsterdam Pharma made up 0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #493 holding.
Ensign Peak Advisors first reported a position in NewAmsterdam Pharma in Q4 2022 and has held it in 11 quarters since.
Ensign Peak Advisors's NewAmsterdam Pharma position peaked at $19.3M in Q4 2025.
195 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.